Stockholm - Free Realtime Quote SEK
CombiGene AB (publ) (COMBI.ST)
As of 1:20 PM GMT+2. Market Open.
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Peter Ekolind | Chief Executive Officer | 893.49k | -- | 1964 |
| Associate Prof. David Woldbye | Scientific Founder | -- | -- | 1963 |
| Prof. Merab Kokaia Ph.D. | Scientific Founder | -- | -- | 1956 |
| Ms. Louise Aspenberg | Chief Financial Officer | -- | -- | 1976 |
| Ms. Annika Ericson | Chief Scientific Officer | -- | -- | -- |
CombiGene AB (publ)
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 10
Description
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Liding?, Sweden.
Corporate Governance
CombiGene AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
Related Tickers
KAN.ST Kancera AB (publ)
1.8800
-0.42%
SPRINT.ST Sprint Bioscience AB (publ)
1.7500
-1.69%
LPGO.ST Lipigon Pharmaceuticals AB (publ)
0.1820
-1.09%
ELIC.ST Elicera Therapeutics AB (publ)
1.5000
-1.96%
SCOL.ST Scandion Oncology A/S
0.1290
-0.77%
FLUI.ST Fluicell AB (publ)
0.0748
+1.63%
XBRANE.ST Xbrane Biopharma AB (publ)
0.2110
+17.22%
BINV.ST BioInvent International AB (publ)
43.05
-3.91%
ONCO.ST Oncopeptides AB (publ)
2.0800
-0.24%
EXPRS2.ST ExpreS2ion Biotech Holding AB (publ)
0.8730
-2.57%